Work

Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC

Year: 2021

Type: article

Study design: Observational Study

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.07.032

Authors: Deborah B. Doroshow, Wei Wei, Swati Gupta, Jon Zugazagoitia, Charles Robbins, Blythe Adamson, David L. Rimm

Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Yale University, Merck & Co., Inc., Rahway, NJ, USA (United States), Hospital Universitario 12 De Octubre, Flatiron Health (United States), Yale Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Merck, Roche, Sanofi, Ipsen Biopharmaceuticals, Navigate BioPharma, PerkinElmer, Flatiron Health, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences, National Center for Advancing Translational Sciences

Awards: Medical Scientist Training Program, Yale Clinical and Translational Science Award, Cancer Center Support Grant

OpenAlex ID: W3194392268

FWCI: 1.885

Cites: 13

Cited by: 32

Related to: 10